GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Replek AD (XMAE:REPL) » Definitions » Return-on-Tangible-Asset

Replek AD (XMAE:REPL) Return-on-Tangible-Asset : 3.08% (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Replek AD Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Replek AD's annualized Net Income for the quarter that ended in Mar. 2025 was MKD92 Mil. Replek AD's average total tangible assets for the quarter that ended in Mar. 2025 was MKD2,970 Mil. Therefore, Replek AD's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was 3.08%.

The historical rank and industry rank for Replek AD's Return-on-Tangible-Asset or its related term are showing as below:

XMAE:REPL' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.75   Med: 6.83   Max: 10.89
Current: 6.62

During the past 13 years, Replek AD's highest Return-on-Tangible-Asset was 10.89%. The lowest was 3.75%. And the median was 6.83%.

XMAE:REPL's Return-on-Tangible-Asset is ranked better than
68.69% of 1022 companies
in the Drug Manufacturers industry
Industry Median: 2.615 vs XMAE:REPL: 6.62

Replek AD Return-on-Tangible-Asset Historical Data

The historical data trend for Replek AD's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replek AD Return-on-Tangible-Asset Chart

Replek AD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.16 6.39 3.75 10.89 7.64

Replek AD Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.81 1.70 -3.10 23.88 3.08

Competitive Comparison of Replek AD's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Replek AD's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Replek AD's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Replek AD's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Replek AD's Return-on-Tangible-Asset falls into.


;
;

Replek AD Return-on-Tangible-Asset Calculation

Replek AD's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=224.196/( (2896.192+2970.194)/ 2 )
=224.196/2933.193
=7.64 %

Replek AD's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=91.576/( (2970.194+0)/ 1 )
=91.576/2970.194
=3.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Replek AD  (XMAE:REPL) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Replek AD Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Replek AD's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Replek AD Business Description

Traded in Other Exchanges
N/A
Address
Kozle 188, Skopje, MKD
Replek AD is engaged in the development, design and production of generic medicines. The company develops drugs in different pharmaceutical therapeutic categories including anti-platelet, lipid-lowering, atypical antipsychotic, anti-infective, among others. It manufactures drugs in different forms including tablets, capsules, oral solutions, creams and ointments. Its product portfolio consists of Clopidogrel, Atorvastatin, Simvastatin, risperidone, Clarythromycin, Ciprofloxacin, Meloksikam, Risperidon, terazosin, among others. Replek also offers cannabis oil products, food supplements and cosmetics.